Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has informed that certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient (API) used in the product. The company is investigating the root cause and taking appropriate measures to ensure product quality. Until the issue is resolved, commercial supplies of the product will be delayed for a certain period of time. There is no impact on patient safety or on the product's existing global regulatory filings. The company remain committed to ensuring reliable global supplies of this important metabolic therapy. The management of the Company will host a conference call on Thursday, July 9, 2026 at 16:30 – 17:00 IST 07:00 – 07:30 ET to discuss the topic and answer any questions from the participants. The Pre-register link to join is enclosed. The transcript of the conference call will be available on the Company’s website: www.drreddys.com.

The above information is a part of company’s filings submitted to BSE.